Neuland Laboratories Limited
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
What Neuland files
- Others73
- Investor Meet46
- Important30
- Updates16
- Board Meeting8
- PPTs8
Neuland Laboratories has committed ₹126 Cr via internal accruals to acquire ~134 acres in Kakinada for future growth. Management also holds a right of first refusal for an additional 66 acres, pushing potential total land to ~200 acres. This bold land bank expansion signals strong long-term capacity scaling ahead.
US FDA inspected Neuland Laboratories' Unit 3 facility. One observation was noted for procedural improvements in water and environmental monitoring for new organisms. The company will address this finding.
Neuland adds 18 KL capacity at Unit 1 for ₹39.8 Cr via internal funds, catering to demand. A strategic partnership with Gland Pharma, secured by a ₹40 Cr guarantee, will establish ~1400 kg annual sterile API capacity for complex injectables, enhancing global supply.
Neuland Labs has commenced commercial production of additional capacities at its Unit 1 and Unit 3. This operational expansion significantly boosts manufacturing capabilities, setting the stage for increased output and potential revenue growth.
Neuland Labs will hold its 42nd virtual Annual General Meeting. Investors can access the AGM notice and annual report online. Details provided for shareholders to register emails or request physical copies.